Nineteen patients were studied in a double-blind cross-over trial. On the first day the midday dose of cimetidine was replaced by either intramuscular cimetidine 200 mg and a placebo tablet, or a placebo injection and cimetidine 200 mg by mouth. The next day the alternative treatment was given, the order being randomised. The two injections were given into opposite buttocks. Blood samples for creatine kinase activity were taken immediately before, and 24 hours after, each injection. Pain at the injection site was assessed as none, mild, moderate, or severe 10 minutes and six hours after each injection, and at the same time the site was inspected for any local reaction. The remaining 19 patients received intramuscular cimetidine 200 mg six hourly for 24 hours, oral cimetidine being omitted. Each injection site was numbered serially, and two to four hours after the last injection the appearance of each site was noted.
The cimetidine injection (200 mg in 2 ml) for intramuscular use was the same formulation as the standard intravenous preparation. The placebo injection was 2 ml 0-9 % sodium chloride. All injections were given by trained nursing staff. Written informed consent was obtained from each patient, and the study had the approval of the hospital ethical committee.
After a single intramuscular injection of cimetidine one patient reported mild pain at 10 minutes that had resolved by six hours and another had moderate pain at six hours that had disappeared by the next day. After placebo injection two other patients reported mild pain at six hours but none had pain at 10 minutes. The injection sites appeared normal except after a placebo injection in one patient, who had erythema at 10 minutes that had resolved by six hours. Serum creatine kinase activity remained normal after all injections. One patient felt light-headed transiently after injection of cimetidine, while another complained of aching in the buttock for a few hours after both injections.
Of the 19 patients receiving intramuscular cimetidine six hourly, 14 had no reaction at any of the injection sites. One patient had erythema with some swelling at one site and erythema alone at another site. The remaining four patients had erythema at one injection site. No adverse events occurred and no patient had to be withdrawn from either part of the study.
Comment
Our study showed that reactions at the injection site were uncommon and as likely with placebo as with intramuscular cimetidine. Though parenteral cimetidine may be overused by hospital doctors,' oral medication cannot be given to patients with an ileus or persistent vomiting. Because of occasional reports of hypotension2 and cardiac arrhythmias3 after intravenous cimetidine many hospitals do not allow nurses to give the drug by this route.
Peak plasma concentrations after intramuscular cimetidine are 30-50% of those achieved after similar intravenous doses, and there is no significant difference in bioavailability (D Rowley-Jones, personal communication). Intramuscular administration of cimetidine is therefore a convenient and safe alternative to intravenous administration when the parenteral route is indicated. 
Family study
The brachydactyly consisted of hypoplasia of the second, third, and fifth middle phalanges of both hands (figure), the severity of the condition varying among family members. In some cases the hypoplasia was restricted to the fifth finger, whereas in others the fourth and fifth metacarpals were also affected. One subject had changes in the segmental ratios of phalanges and metatarsals in both feet.
Brachydactyly had been present in five out of seven siblings. Three of the five had died of colorectal cancer, and the other two had died of unrelated disorders at 29 and 68 years of age. One of the two siblings without hand
